

2018 State of Minnesota Review:
Medical Cannabis Studies Relating to Chemical Compositions & (THC/CBD) Dosages for
Qualifying Medical Conditions

<http://www.health.state.mn.us/topics/cannabis/practitioners/dosagesandcompositions2018.pdf>

THC Dose Ranges per 2018 Minnesota Review Applied to Eligible Iowa Conditions (Daily & 90 Day Supply)						
	Daily Dose Range (Milligrams)			90 Day Dose Supply/Equivalency (Grams)		
	Low Range (mg)		High Range (mg)	Low Range (grams)		High Range (grams)
Cancer - Chronic Pain	25	to	25	2.25	to	2.25
Cancer - Nausea/Vomiting	30	to	80	2.7	to	7.2
Cancer - Cachexia/Wasting	30	to	60	2.7	to	5.4
MS	n/a	to	n/a	n/a	to	n/a
Seizures	n/a	to	n/a	n/a	to	n/a
AIDS/HIV	5	to	40	0.45	to	3.6
Crohns	n/a	to	n/a	n/a	to	0
ALS	3	to	10	0.27	to	0.9
Terminal - Pain	25	to	25	2.25	to	2.25
Terminal - Nausea	30	to	80	2.7	to	7.2
Terminal - Cachexia/Wasting	30	to	60	2.7	to	5.4
Parkinsons	n/a	to	n/a	n/a	to	n/a
Untreatable Pain	25	to	25	2.25	to	2.25

*1,000 mg = 1 gram

Currently in Iowa by Comparison:

The largest amount of THC in a single product form and package of state regulated mCBD known to be on the market in Iowa = 600 milligrams in 30 capsules of MedPharm's *Aliviar Comfort* (by rule, a 90-day supply of mCBD may be dispensed to a patient at any one time, but dose guidance is discretionary).

FDA-Approved Synthetic THC Medications & Recommended Doses:

- Marinol: 2.5mg 2x/day for anorexia, 5mg 4-6x/day for nausea = daily dose range 5-30 milligrams = 90 day dose range 0.45-2.7 grams.
- Cesamet: 1-2mg 2x/day to 6mg 3x/day for chemotherapy = daily dose range 2-18 milligrams = 90 day dose range 0.002-0.018 grams.

Limited Access Marijuana Product Laws: Low THC/High CBD—Cannabidiol

Updated by the National Conference of State Legislatures (NCSL) 1-23-19

State	Conditions	CBD Minimum	THC Maximum	In-State Production
1. Alabama 2016	6+: Epilepsy, life-threatening seizures, wasting syndrome, chronic pain, nausea, muscle spasms & other severe conditions resistant to meds	NA	<3.0%	No
2. Georgia 2015	8: End stage cancer, ALS, MS, seizures, Crohn's, mitochondrial, Parkinson's & Sickle Cell	Equal to THC	<5.0%	University research related
3. Iowa 2017	11+: Chronic pain, nausea, Cachexia, MS, ALS, AIDS/HIV, Crohn's, Parkinson's, most terminal illnesses & others TBD... *Ulcerative Colitis & *severe pediatric autism (*added by rule in 2019)	NA	3.0%	Commercial
4. Indiana 2017	1: Treatment resistant epilepsy	5.0%	0.3%	Not defined
5. Kentucky 2014	1: Intractable seizures	Only CBD	NA	University research related
6. Mississippi 2014	1: Debilitating epilepsy or related	15% (or 50mg/ml)	0.5%	University research related
7. North Carolina 2015	1: Intractable epilepsy	5.0%	<0.9% & no other psychoactive substance	University research related
8. South Carolina 2014	1: Severe forms of epilepsy or seizures	>15% (or 98% by total volume)	0.9% from lab	Clinical trials
9. Tennessee 2015	1: Intractable seizures	NA	<0.9%	University research related
10. Texas 2015	1: Intractable epilepsy	10%	0.5%	Commercial
11. Virginia 2015	1: Intractable epilepsy	15%	5.0%	No
12. Wisconsin 2013	1: Severe seizure disorders	NA	NA, "no psychoactive effect"	No, FDA-approved or out of state
13. Wyoming 2015	1: Intractable epilepsy or seizure disorders	5%	0.3%	No

Source: National Conference of State Legislatures (NCSL) Update 1-23-19: <http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx>.

-Does not include state medical marijuana/cannabis program laws.